ArticleBasic and clinical neuroscience
Coenzyme Q10 Suppression of Cue-related Reinstatement Through Cognition Improvement and Hippocampal Increase in BDNF Expression in Morphine-dependent Male Rats.
Article in Basic and clinical neuroscience. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Opioid dependence significantly disrupts cognitive activities such as learning and memory, which may be the reason for a return to drug use. Morphine (MOR) can increase oxidative damage in the brain. We aim to investigate the effect of coenzyme Q10 (CoQ10) on cognitive impairment, cue-related reinstatement, and expression of brain-derived neurotrophic factor (BDNF) in MOR-dependent rats. Methods: In this study, 40 male Wistar rats (200-220 g) were divided into 5 experimental groups (n=8) as follows: Oil group, MOR+oil group, MOR+CoQ10-100 group, MOR+CoQ10-200 group, and MOR+CoQ10-400 group. The rats were administered increasing doses of MOR (25 to 100 mg/kg, SC) once daily. After 21 days of addiction, CoQ10 treatment is administered by gavage at doses of 100, 200, and 400 mg/kg once daily for one month. CoQ10 is dissolved in 1 mL of sesame oil and administered. Behavioral assessments were performed using a novel object recognition (NOR) test, working memory in the Y-maze, social interaction, and conditioned place preference (CPP). The expression of BDNF was assessed in the hippocampus through immunohistochemistry. Results: Treatment with CoQ10 at a dosage of 100, 200, and 400 mg/kg within 4 weeks resulted in a significant improvement in the NOR task (P<0.01, P<0.001), working memory in the Y-maze (P<0.01, P<0.001), social interaction (P<0.001), cue-related reinstatement in the CPP (P<0.01, P<0.001) and significantly increased expression of BDNF (P<0.001) in the hippocampus of male rats. Conclusion: CoQ10 could improve cognitive impairment and reduce reinstatement in MOR-addicted male rats. Histologic examination confirmed the neuroprotective effects of CoQ10 in the hippocampus. CoQ10 could be a potential therapeutic agent for MOR-induced cognitive impairment and relapse.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.